Evidence map›Paper›PMID 24117105›Full record

ArticleBritish journal of pharmacology2014

Cell death and the mitochondria: therapeutic targeting of the BCL-2 family-driven pathway.

M J Roy, A Vom, P E Czabotar, G Lessene

Abstract read
In one paragraph

Article in British journal of pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Targeting BCL2 pathways in CLL: a story of resistance and ingenuity.Cancer drug resistance (Alhambra, Calif.) · 2023
    Review
  13. Article
  14. Article
  15. Article
  16. The Role of Bcl-xL Protein in Viral Infections.International journal of molecular sciences · 2021
    Review
  17. Review
  18. Article
  19. Cell Death Pathways in Lymphoid Malignancies.Current oncology reports · 2020
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

M J RoyDivisions of Chemical and Structural Biology, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Vic, Australia; Department of Medical Biology, The University of Melbourne, Melbourne, Vic, Australia.
A Vom
P E Czabotar
G Lessene

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The principal biological role of mitochondria is to supply energy to cells; although intriguingly, evolution has bestowed another essential function upon these cellular organelles: under physiological stress, mitochondria become the cornerstone of apoptotic cell death. Specifically, mitochondrial outer membrane permeabilization (MOMP) allows cell death factors such as cytochrome c to be released into the cytoplasm, thus inducing caspase activation and the eventual destruction of essential cellular components. Proteins of the B-cell lymphoma 2 (BCL-2) family control the tightly regulated pathway that causes MOMP. The equilibrium between pro-survival and pro-apoptotic members of the BCL-2 family dictates the fate of cells, the homeostasis of organs and, by extension, the health of whole organisms. Dysregulation of this equilibrium is involved in a large number of diseases such as cancer, autoimmunity and neurodegenerative conditions. Modulating the activity of the BCL-2 family of proteins with small molecules or peptides is an attractive but challenging therapeutic goal. This review highlights the latest developments in this field and provides evidence that this strategy is likely to have a positive effect on the treatment of still poorly addressed medical conditions.

Indexed as

Cell DeathDrug DiscoveryHumansModels, BiologicalMolecular Targeted TherapyPeptidesProtein Structure, TertiaryProto-Oncogene Proteins c-bcl-2Signal TransductionSulfonamidesPeptidesProto-Oncogene Proteins c-bcl-2SulfonamidesapoptosisBCL-2 familycancerneurodegenerative diseasesprotein-protein interactions

Identifiers

PMID24117105
PMCPMC3976616

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.